3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
181
Lymphoma
97
Lymphoma, Large B-Cell, Diffuse
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
79
Sarcoma
69
Hodgkin Disease
54
Lymphoma, Non-Hodgkin
41
Triple Negative Breast Neoplasms
37
Burkitt Lymphoma
36
Lymphoma, Mantle-Cell
32
Leukemia
32
Lymphoma, Follicular
30
Multiple Myeloma
28
Carcinoma, Hepatocellular
28
Neoplasm Metastasis
23
Ovarian Neoplasms
21
Neoplasms
21
Lymphoma, Large-Cell, Anaplastic
18
Osteosarcoma
17
Lymphoma, B-Cell
17
Prostatic Neoplasms
16
Neuroblastoma
15
Lymphoma, T-Cell, Peripheral
15
Urinary Bladder Neoplasms
14
Recurrence
13
Lymphoma, Large-Cell, Immunoblastic
13
Inflammatory Breast Neoplasms
13
Immunoblastic Lymphadenopathy
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Stomach Neoplasms
10
Interventions
Cyclophosphamide
10
fludarabine
7
Rituximab
6
Bendamustine Hydrochloride
5
venetoclax
4
obinutuzumab
4
Lenalidomide
4
ofatumumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Vincristine
3
Immunotherapy, Adoptive
3
pirtobrutinib
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
ricolinostat
1
pembrolizumab
1
pegaspargase
1
nelarabine
1
idelalisib
1
blinatumomab
1
Whole-Body Irradiation
1
Prednisolone
1
Pentostatin
1
Panobinostat
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, B-Cell
×
Doxorubicin
×
Clear all
NCT03899337
2023-01-09
STELLAR
University of Birmingham
Phase 2
Recruiting
105 enrolled